-
-
-
-
-
-
-
UBS Reiterates Neutral Rating on Abbvie (ABBV)
-
-
-
-
-
-
-
AbbVie presents real-world Vraylar data at Psych Congress 2026
-
-
-
-
-
-
-
Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuation
-
-
-
-
-
-
-
AbbVie Q2 earnings preview: analysts eye immunology growth, pipeline
-
-
-
-
-
-
-
Abbvie (ABBV) PT Raised to $280 at RBC Capital
-
-
-
-
-
-
-
FDA selects 7 companies for domestic drug manufacturing pilot
-
-
-
-
-
-
-
EU approves AbbVie's Skyrizi for children with plaque psoriasis
-
483,111 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


